drugset
Drugs / TQB2858
last change Dec 2025 re-read 2 minutes ago

TQB2858

Protein / enzyme biologic

Developed for
cancer · cancer of unknown primary site · cervical cancer · endometrial carcinoma · nasopharyngeal carcinoma · sarcoma · soft tissue sarcoma
Investigated by
Chia Tai Tianqing Pharmaceutical Group Co., Ltd. · Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd.

Trials 7 · a red edge is where a trial was stopped

today NCT05262101 · Ph 2 NCT05193604 · Ph 1 NCT05198531 · Ph 1/2 NCT05154630 · Ph 1/2 NCT05121363 · Ph 2 NCT05068921 · Ph 1 NCT04805060 · Ph 1
20222023202420252026
PhaseRegistry idDatesIndicationSponsorStatusOutcome
Phase 13 trials
Phase 1 NCT05193604 Mar 2022 → Nov 2023 — Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd. Terminated No outcome recorded
Phase 1 NCT05068921 Dec 2021 → May 2023 cervical cancer Chia Tai Tianqing Pharmaceutical Group Co., Ltd. Unknown No outcome recorded
Phase 1 NCT04805060 Apr → Dec 2021 cancer Chia Tai Tianqing Pharmaceutical Group Co., Ltd. Unknown No outcome recorded
Phase 1/22 trials
Phase 1/2 NCT05154630 Jan 2022 → Mar 2023 cancer of unknown primary site, soft tissue sarcoma Chia Tai Tianqing Pharmaceutical Group Co., Ltd. Terminated No outcome recorded
Phase 1/2 NCT05198531 Jan → Oct 2022 nasopharyngeal carcinoma Chia Tai Tianqing Pharmaceutical Group Co., Ltd. Unknown No outcome recorded
Phase 22 trials
Phase 2 NCT05262101 May 2022 → Jun 2023 sarcoma Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd. Terminated No outcome recorded
Phase 2 NCT05121363 Dec 2021 → May 2023 endometrial carcinoma Chia Tai Tianqing Pharmaceutical Group Co., Ltd. Unknown No outcome recorded

Evidence & citations 4 cited values

Every value below carries the sentence it was read from. 7 sources stand behind the page.

FieldValueCited text
Known as TQB2858 ClinicalTrials.gov intervention name — accepted as the source's own label NCT04805060 ↗
6

NCT05154630 ↗

NCT05193604 ↗

NCT05262101 ↗

NCT05068921 ↗

NCT05121363 ↗

NCT05198531 ↗
Action Inhibit “anti-programmed death ligand 1” NCT05068921 ↗
Modality Protein / enzyme biologic “bi-functional fusion protein” NCT05068921 ↗
Route Intravenous “TQB2858 administered intravenously (IV)” NCT04805060 ↗